• Sanket Patel Department of Pharmacology and Clinical Pharmacy, Ramanbhai Patel College of Pharmacy, Charotar University of Science and Technology (Charusat), Charusat Campus, Changa 388421, Gujarat, India
  • B. G. Patel
  • Kalpesh Gohel


Objective: The objective of present study was to evaluate incidence and risk factors for the development of new-onset diabetes after transplantation (NODAT) after kidney transplantation at our center.

Methods: A total 79 nondiabetic patients who underwent living donor kidney transplantation from January 2014 to August 2014 were prospectively enrolled. All the patients were followed for one year. All the patients received the same protocol of immunosuppressive therapy. NODAT was defined as if a patient had HbA1c ≥ 6.5%, fasting venous plasma glucose ≥126 mg/dl, or was receiving diet or medical therapy for diabetes.

Results: The incidence of NODAT was 29.9% after one year. Risk factors associated with the development of NODAT included older age (OR: 1.07; p<0.05), family history (OR: 3.58; P<0.05), hepatitis C virus (HCV) positivity (OR: 11.15; p<0.05), obesity (OR: 4.28; p<0.05), pre-transplant triglycerides (OR: 1.01; p<0.005) and cholesterol level (OR: 1.01; p<0.005).

Conclusion: The prevalence of potentially modifiable risk factors in our study cohort was overweight recipients and pretransplant HCV infection, serum triglycerides, and cholesterol levels.

Keywords: New-onset Diabetes after transplantation, Kidney transplantation, Tacrolimus, Hepatitis C virus.


Download data is not yet available.


Miles AM, Sumrani N, Horowitz R, Homel P, Maursky V, Markell MS, et al. Diabetes mellitus after renal transplantation: as deleterious as non-transplant-associated diabetes? Transplantation 1998;65:380-4.

Cosio FG, Pesavento TE, Kim S, Osei K, Henry M, Ferguson RM. Patient survival after renal transplantation: IV. Impact of post-transplant diabetes. Kidney Int 2002;62:1440-6.

Hjelmesaeth J, Hartmann A, Leivestad T, Holdaas H, Sagedal S, Olstad M, et al. The impact of early-diagnosed new-onset post-transplantation diabetes mellitus on survival and major cardiac events. Kidney Int 2006;69:588-95.

Montori VM, Velosa JA, Basu A, Velosa JA, Gabriel SE, Kudva YC. Posttransplantation diabetes: a systematic review of the literature. Diabetes Care 2002;25:583-92.

Chakkera HA, Weil EJ, Swanson CM, Dueck AC, Heilman RL, Reddy KS, et al. Pretransplant risk score for new-onset diabetes after kidney transplantation. Diabetes Care 2011;34:2141-5.

Greenspan LC, Gitelman SE, Leung MA, Glidden DV, Mathias RS. Increased incidence in post-transplant diabetes mellitus in children: a case-control analysis. Pediatr Nephrol 2002;17:1-5.

Cosio FG, Kudva Y, van der Velde M, Larson TS, Textor SC, Griffin MD, et al. New-onset hyperglycemia and diabetes are associated with increased cardiovascular risk after kidney transplantation. Kidney Int 2005;67:2415-21.

Kasiske BL, Snyder JJ, Gilbertson D, Matas AJ. Diabetes mellitus after kidney transplantation in the United States. Am J Transplant 2003;3:178-85.

Montori VM, Basu A, Erwin PJ, Velosa JA, Gabriel SE, Kudva YC. Posttransplantation diabetes. A systematic review of the literature. Diabetes Care 2002;25:583-92.

Gourishankar S, Jhangri GS, Tonelli M, Wales LH, Cockfield SM. Development of diabetes mellitus following kidney trans-plantation: a Canadian experience. Am J Transplant 2004;4: 1876-82.

Cosio FG, Pesavento TE, Osei K, Henry ML, Ferguson RM. Post-transplant diabetes mellitus: Increasing incidence in renal allograft recipients transplanted in recent years. Kidney Int 2001;59:732-7.

Ghisdal L, Van Laecke S, Abramowicz MJ, Vanholder R, Abramowicz D. New-onset diabetes after renal transplantation risk assessment and management. Diabetes Care 2012;35:181-8.

Shah T, Kasravi A, Huang E, Hayashi R, Young B, Cho YW, et al. Risk factors for the development of new-onset diabetes mellitus after kidney transplantation. Transplantation 2006;82:1673-6.

Davidson J, Wilkinson A, Dantal J, Dotta F, Haller H, Hernandez D, et al. New-onset diabetes after transplantation: 2003 international consensus guidelines. Proceedings of an international expert panel meeting. Barcelona Spain Transplantation 2003;75 Suppl 10: SS3-SS24.

Rostaing L, Cantarovich D, Mourad G, Budde K, Rigotti P, Mariat C, et al. Corticosteroid-free immunosuppression with tacrolimus, mycophenolate mofetil, and daclizumab induction in renal transplantation. Transplantation 2005;79:807-14.

Prakasha J, Rathore SS, Singh TB, Choudhury TA, Prabhakar, Usha. New-onset diabetes after transplantation (NODAT): analysis of pre-transplant risk factors in renal allograft recipients. Indian J Transplantation 2012;6:1-6.

Bora GS, Guleria S, Reddy VS, Tandon N, Gupta N, Gupta S, et al. Risk factors for the development of new-onset diabetes mellitus in a living related renal transplant program. Transplant Proc 2010;42:4072-3.

Bloom RD, Rao V, Weng F, Grossman RA, Cohen D, Mange KC. Association of hepatitis C with posttransplant diabetes in renal transplant patients on tacrolimus. J Am Soc Nephrol 2002;13:1374-80.

Siraj ES, Abacan C, Chinnappa P, Wojtowicz J, Braun W. Risk factors and outcomes associated with posttransplant diabetes mellitus in kidney transplant recipients. Transplant Proc 2010;42:1685-9.



How to Cite

Patel, S., B. G. Patel, and K. Gohel. “INCIDENCES OF-AND RISK FACTOR FOR NEW ONSET DIABETES AFTER TRANSPLANTATION IN LIVE DONOR KIDNEY TRANSPLANTATION: A PROSPECTIVE SINGLE CENTRE STUDY”. International Journal of Pharmacy and Pharmaceutical Sciences, vol. 8, no. 2, Feb. 2016, pp. 230-3,



Original Article(s)